Podcast Medicom Medical Publishers: Recent Episodes

Medicom Medical Publishers

Exciting abstracts presented at the major medical conferences

View Details

Dr Rachel Giles guides you through clinical updates presented at the ESC Congress 2020:

  1. Packer M. EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes.
  2. Olivotto I. EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy.
  3. Kirchhof P. EAST – AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation.
  4. Pieske B. PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF.
  5. Nidorf SM. LoDoCo2 Low-Dose Colchicine in Coronary Disease
  6. Lopes R. BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19.

View Details

Summary of articles from the ISTH 2020 Virtual Congress:

  1. Stals MAM, et al. Thrombotic Complications: SARS-COV-2 versus Influenza. LB/CO01.4, ISTH Virtual Congress 2020, 12-14 July.
  2. Königs C, et al. Safety and Efficacy of rFVIIIFc in Untreated Patients with Haemophilia A. OC 03.2, ISTH 2020 Virtual Congress, 12-14 July.
  3. Nopp S, et al. Outpatient Pulmonary Rehabilitation post-Pulmonary Embolism. PB2457, ISTH Virtual Congress 2020, 12-14 July.
  4. Al-Samkari H, et al. ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non-Small Cell Lung Cancer. OC 10.2.ISTH 2020 Virtual Congress, 12-14 July.
  5. Moustafa F, et al. DOAC bleeding events: atrial fibrillation vs venous thromboembolism. PB1128, ISTH 2020 Virtual Congress, 12-14 July.
  6. Beyer-Westendorf J, et al. Pregnancy and DOACs. SOA 10.03, ISTH Virtual Congress 2020, 12-14 July.

View Details

Summary of articles from the EAU20 Virtual Congress:

  1. Stolzenburg J-U, et al. Continence Following Robot-Assisted (R-LRPE) and Conventional Laparoscopic Radical Prostatectomy (LRPE) – Results of a Prospective, Randomized, Multicenter, Patient Blinded Study.
  2. Grimm MO, et al. Recurrent risk in patients with high grade non-muscle invasive bladder carcinoma in the randomized phase III clinical trial ‘NIMBUS’ stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?
  3. Shore N, et al. Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients (pts) with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC).
  4. Hofman M, et al. ProPSMA Study: a prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy.
  5. Barber N et al. Two year outcomes after aquablation compared to TURP: results from a blinded randomized trial.
  6. Josefsson AS, et al. A prospective randomised study of bicalutamide +/- docetaxel for non-metastatic prostate cancer with a rising PSA (SPCG-14).
  7. Tandoğdu Z et al. Urosepsis: Hot data from the SERPENS study.

View Details

Summary of articles from the AAD VMX 2020:

  1. Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020.
  2. Khanna R et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
  3. Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020.
  4. Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  5. Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
  6. Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.

View Details

Summary of articles presented at the EHA25 Virtual Congress:

  1. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A DiNardo C. Jun 14, 2020; 303390; LB2601
  2. SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY Kastritis E. Jun 14, 2020; 303396; LB2604
  3. POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG. Borchmann P. Jun 12, 2020; 294921; S101
  4. TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY 'FORUM' ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP. Peters C. Jun 12, 2020; 294922; S102
  5. PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-204 Zinzani P. Jun 12, 2020; 303389; LB2600

View Details

Summary of 6 articles presented at the European E-Congress of Rheumatology:

  1. COVID-19 and inflammatory rheumatic disease: some key issues answered
  2. Upadacitinib provides fast onset of improvement in psoriatic arthritis
  3. Lower venous thromboembolism risk with TNF inhibitors in rheumatoid arthritis
  4. New nanoparticle promising future agent in rheumatoid arthritis
  5. Rozibafusp alfa effective and tolerable in rheumatoid arthritis
  6. Olokizumab significantly improves rheumatoid arthritis features

View Details

Summary of 6 articles presented at the ASCO20 Virtual Meeting:

  1. CASPIAN - ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint
  2. E2108 - Advanced breast cancer: locoregional therapy does not improve OS
  3. EORTC 1325/KEYNOTE-054 - Adjuvant pembrolizumab: durable RFS for Stage III melanoma
  4. JAVELIN Bladder 100 - Urothelial cancer: avelumab works as maintenance therapy
  5. KEYNOTE-177 - Pembrolizumab as first-line in MSI-H mCRC
  6. ADAURA - Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

View Details

Summary of 6 articles presented at the EAN 2020 Virtual Meeting:

  1. Long-term safety of ND0612 in idiopathic Parkinson’s disease
  2. Reassuring real-world safety profile of 3 CGRP inhibitors
  3. Long-term cardiovascular safety of erenumab in migraine patients
  4. Extubation after thrombectomy: the sooner, the better
  5. Serum NfL predicts long-term clinical outcomes in MS
  6. Neurological manifestations of COVID-19 in Europe

View Details

Order of abstracts:

  1. Kim et al - TICO trial - Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
  2. Dangas et al - TWILIGHT-COMPLEX substudy - Significant less bleeding with ticagrelor monotherapy after complex PCI
  3. Lim et al - EXPAND trial - MitraClip safe and effective in real-world setting
  4. Ho et al - MAVERICK-HCM trial - Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
  5. Raal et al - Evinacumab significantly reduces LDL-C in homozygous FH patients
  6. Bhatt et al - REDUCE-IT EPA analysis - Higher serum levels of eicosapentaenoic acid correlate with reduced CV events

View Details

Order of abstracts:

  1. Nijenhuis et al - POPular TAVI trial - Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
  2. Ramlawi et al - TAVR safe and effective in low-risk bicuspid aortic stenosis patients
  3. Desai et al - STS/ACC TVT Registry - TAVR model reveals differences in hospital outcomes
  4. Alexander et al - AUGUSTUS trial - Apixaban preferred over aspirin in AF patients with recent ACS/PCI
  5. Hiatt et al - Subgroup analysis VOYAGER PAD
  6. Kim et al - No role for sodium nitrite in out-of-hospital cardiac arrest

View Details

Order of abstracts:

  1. Armstrong et al - VICTORIA trial - Vericiguat shows beneficial effects in very high-risk HF population
  2. Bonaca et al - VOYAGER-PAD trial - Rivaroxaban and aspirin effective and safe for PAD patients
  3. Pereira et al - TAILOR-PCI trial - TAILOR-PCI misses endpoint but still provides valuable insights
  4. Leon et al - PARTNER 3 trial - 2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
  5. Agnelli et al - CARAVAGGIO trial - Apixaban offers new perspective for cancer patients in need of anticoagulation
  6. Samama et al - Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery

View Details

Order of abstracts:

  1. OP23 Vermeire et al - VISIBLE 2 trial
  2. OP28 Jongsma et al
  3. DOP13 Danese et al - STARDUST trial
  4. DOP39 Kobayashi et al
  5. OP01 Colombel et al - SERENE-UC trial